Regencell Bioscience's 15min chart triggers MACD Death Cross, KDJ Death Cross.

Regencell Bioscience's 15-minute chart exhibits bearish technical indicators, as evidenced by the MACD Death Cross and KDJ Death Cross on October 9th, 2025 at 10:00. This suggests that the stock price may continue to decline, with momentum shifting towards the downside and potentially leading to further decreases.

Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) has experienced significant volatility in its stock price, with a recent rebound following a dramatic decline. The stock's latest performance, however, is showing bearish technical indicators, which may suggest further downward movement.

On October 9th, 2025, at 10:00, Regencell's 15-minute chart exhibited a MACD Death Cross and KDJ Death Cross. These indicators are often seen as signals of a potential reversal in price trends, with the MACD Death Cross indicating a bearish crossover and the KDJ Death Cross suggesting a shift in momentum towards the downside Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1]. This technical analysis suggests that the stock price may continue to decline, potentially leading to further decreases.

Regencell, founded in 2014, focuses on combining traditional Chinese medicine with modern biomedical approaches to address neurodegenerative disorders. The company's stock price has shown extreme volatility, soaring from $1 to $84 before plummeting below $10 Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1]. Despite its volatility, the stock has seen renewed buying interest, climbing above $20 after consolidating near $12 Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1].

The company's market capitalization has grown to around $10 billion, but it remains a small operation with only 12 employees. Regencell reported a net loss of $4.74 million in 2024, underscoring its early-stage status Regencell Goes From Collapse to Comeback: RGC Stock Targets $30 After $20 Break^[1]. The stock's high volatility continues to intrigue traders, but it also serves as a reminder of the risks associated with speculative biotech investing.

Morningstar's quantitative ratings for Regencell suggest that the stock is trading at a 776% premium, indicating a significant overvaluation compared to its fair value of $27.24 Regencell Bioscience Holdings Ltd RGC^[2]. The high uncertainty rating further underscores the stock's volatile nature.

Regencell's latest rebound shows that investor appetite for high-volatility biotech stories remains strong, but the technical challenges faced by the stock may indicate a potential downturn. Investors should closely monitor the company's clinical progress, revenue generation, and regulatory milestones to gauge its long-term prospects.